{"name":"Sandoz Group AG","slug":"sandoz","ticker":"SDZ","exchange":"SIX","domain":"sandoz.com","description":"Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars.","hq":"Basel, Switzerland","founded":2003,"employees":"~75,000","ceo":"Richard Saynor","sector":"Generics & Biosimilars","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153.4B","metrics":{"revenue":11200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-19","label":"Canasa Phase 3 readout (Ulcerative Colitis (UC))","drug":"Canasa","drugSlug":"canasa","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"ZIEXTENZO Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"ZIEXTENZO","drugSlug":"pegfilgrastim-bmez","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"ZIEXTENZO Phase 2 readout (Renal Pelvis and Ureter Urothelial Carcinoma)","drug":"ZIEXTENZO","drugSlug":"pegfilgrastim-bmez","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-31","label":"Canasa Phase 2 readout (Ulcerative Colitis, Fecal Microbiota Transplantation)","drug":"Canasa","drugSlug":"canasa","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Eylea EU patent cliff ($1.5B at risk)","drug":"Eylea EU","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Originator rituximab - Rituxan or MabThera patent cliff ($2.5B at risk)","drug":"Originator rituximab - Rituxan or MabThera","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"infectious","drugs":[{"name":"Opana","genericName":"Opana","slug":"opana","indication":"Other","status":"marketed"},{"name":"ANTI-ANGIN® FORMULA","genericName":"ANTI-ANGIN® FORMULA","slug":"anti-angin-formula","indication":"Angina pectoris (stable and unstable)","status":"phase_3"},{"name":"Broncho-munal®","genericName":"Broncho-munal®","slug":"broncho-munal","indication":"Other","status":"phase_3"},{"name":"Canasa","genericName":"Canasa","slug":"canasa","indication":"Other","status":"discontinued"},{"name":"Duragesic","genericName":"Duragesic","slug":"duragesic","indication":"Other","status":"marketed"},{"name":"ENZEEVU","genericName":"AFLIBERCEPT-ABZV","slug":"aflibercept-abzv","indication":"Other","status":"marketed"},{"name":"GME751","genericName":"GME751","slug":"gme751","indication":"Unknown","status":"phase_3"},{"name":"GP2013","genericName":"GP2013","slug":"gp2013","indication":"Other","status":"phase_3"},{"name":"GP2015","genericName":"GP2015","slug":"gp2015","indication":"Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy","status":"phase_3"},{"name":"Generic tacrolimus","genericName":"Generic tacrolimus","slug":"generic-tacrolimus","indication":"Other","status":"marketed"},{"name":"Glucophage 1000 mg","genericName":"Glucophage 1000 mg","slug":"glucophage-1000-mg","indication":"Other","status":"phase_1"},{"name":"HX575 recombinant human erythropoietin alfa","genericName":"HX575 recombinant human erythropoietin alfa","slug":"hx575-recombinant-human-erythropoietin-alfa","indication":"Other","status":"marketed"},{"name":"JUBBONTI","genericName":"DENOSUMAB-BBDZ","slug":"denosumab-bbdz","indication":"Other","status":"marketed"},{"name":"Omnitrope","genericName":"Omnitrope","slug":"omnitrope","indication":"Growth retardation","status":"marketed"},{"name":"ZIEXTENZO","genericName":"PEGFILGRASTIM-BMEZ","slug":"pegfilgrastim-bmez","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"LRG-002","genericName":"LRG-002","slug":"lrg-002","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"SOK583A1","genericName":"SOK583A1","slug":"sok583a1","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"EP2006","genericName":"EP2006","slug":"ep2006","indication":"Anemia in patients with chronic kidney disease","status":"phase_3"},{"name":"ERYPO®, Janssen-Cilag","genericName":"ERYPO®, Janssen-Cilag","slug":"erypo-janssen-cilag","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"GP2013 - A Proposed biosimilar rituximab","genericName":"GP2013 - A Proposed biosimilar rituximab","slug":"gp2013-a-proposed-biosimilar-rituximab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"HX575 epoetin alfa","genericName":"HX575 epoetin alfa","slug":"hx575-epoetin-alfa","indication":"Anemia of chronic kidney disease","status":"phase_3"},{"name":"HX575 epoetin alfa (Sandoz)","genericName":"HX575 epoetin alfa (Sandoz)","slug":"hx575-epoetin-alfa-sandoz","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"HYRIMOZ","genericName":"ADALIMUMAB-ADAZ","slug":"adalimumab-adaz","indication":"Oncology","status":"marketed"},{"name":"Keytruda-EU","genericName":"Keytruda-EU","slug":"keytruda-eu","indication":"Metastatic melanoma","status":"phase_3"},{"name":"MabThera","genericName":"MabThera","slug":"mabthera","indication":"Relapsed or refractory B-cell non-Hodgkin's lymphoma","status":"marketed"},{"name":"Originator rituximab - Rituxan ® or MabThera ®","genericName":"Originator rituximab - Rituxan ® or MabThera ®","slug":"originator-rituximab-rituxan-or-mabthera","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"rare","drugs":[{"name":"Adalimumab - GP2017","genericName":"Adalimumab - GP2017","slug":"adalimumab-gp2017","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Adalimumab - US licensed Humira","genericName":"Adalimumab - US licensed Humira","slug":"adalimumab-us-licensed-humira","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Angal S, topical spray [Menthol]","genericName":"Angal S, topical spray [Menthol]","slug":"angal-s-topical-spray-menthol","indication":"Topical relief of minor muscle and joint pain","status":"phase_3"},{"name":"GP2015 Etanercept","genericName":"GP2015 Etanercept","slug":"gp2015-etanercept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"GP2017 Adalimumab","genericName":"GP2017 Adalimumab","slug":"gp2017-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"TYRUKO","genericName":"NATALIZUMAB-SZTN","slug":"natalizumab-sztn","indication":"Multiple Sclerosis","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"GP2411","genericName":"GP2411","slug":"gp2411","indication":"Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis)","status":"phase_3"},{"name":"Interleukin-3","genericName":"Interleukin-3","slug":"interleukin-3","indication":"Bone marrow failure and aplastic anemia","status":"marketed"},{"name":"LA-EP2006","genericName":"LA-EP2006","slug":"la-ep2006","indication":"Anemia of chronic kidney disease","status":"phase_3"},{"name":"US-licensed epoetin alfa","genericName":"US-licensed epoetin alfa","slug":"us-licensed-epoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Ocrevus-EU","genericName":"Ocrevus-EU","slug":"ocrevus-eu","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"},{"name":"Dopaminergic Agonists","genericName":"Dopaminergic Agonists","slug":"dopaminergic-agonists","indication":"Parkinson's disease","status":"marketed"},{"name":"Ocrevus-US","genericName":"Ocrevus-US","slug":"ocrevus-us","indication":"Relapsing multiple sclerosis","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"ANTI-ANGIN® FORMULA, topical metered spray","genericName":"ANTI-ANGIN® FORMULA, topical metered spray","slug":"anti-angin-formula-topical-metered-spray","indication":"Sore throat pain relief","status":"phase_3"},{"name":"Angal, lozenges [menthol],","genericName":"Angal, lozenges [menthol],","slug":"angal-lozenges-menthol","indication":"Sore throat pain and irritation","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CYB704","genericName":"CYB704","slug":"cyb704","indication":"Age-related macular degeneration (AMD)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"CIMERLI","genericName":"RANIBIZUMAB-EQRN","slug":"ranibizumab-eqrn","indication":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"HX575 epoetin alfa Hexal AG","genericName":"HX575 epoetin alfa Hexal AG","slug":"hx575-epoetin-alfa-hexal-ag","indication":"Anemia of chronic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"CYB704","genericName":"CYB704","slug":"cyb704","phase":"phase_3","mechanism":"CYB704 is a selective inhibitor of complement factor D that reduces complement cascade activation and downstream inflammatory responses.","indications":["Age-related macular degeneration (AMD)"],"catalyst":""},{"name":"GP2411","genericName":"GP2411","slug":"gp2411","phase":"phase_3","mechanism":"GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function.","indications":["Prevention of chemotherapy-induced neutropenia (febrile neutropenia prophylaxis)","Mobilization of peripheral blood progenitor cells for autologous stem cell transplantation"],"catalyst":""},{"name":"LRG-002","genericName":"LRG-002","slug":"lrg-002","phase":"phase_3","mechanism":"LRG-002 is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Ocrevus-EU","genericName":"Ocrevus-EU","slug":"ocrevus-eu","phase":"phase_3","mechanism":"Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Primary progressive multiple sclerosis (PPMS)"],"catalyst":""},{"name":"Opana","genericName":"Opana","slug":"opana","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SOK583A1","genericName":"SOK583A1","slug":"sok583a1","phase":"phase_3","mechanism":"SOK583A1 is a small molecule drug that targets the molecular target.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"ANTI-ANGIN® FORMULA","genericName":"ANTI-ANGIN® FORMULA","slug":"anti-angin-formula","phase":"phase_3","mechanism":"Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload.","indications":["Angina pectoris (stable and unstable)","Prophylaxis of anginal attacks"],"catalyst":""},{"name":"ANTI-ANGIN® FORMULA, topical metered spray","genericName":"ANTI-ANGIN® FORMULA, topical metered spray","slug":"anti-angin-formula-topical-metered-spray","phase":"phase_3","mechanism":"ANTI-ANGIN® FORMULA provides topical anesthetic and anti-inflammatory relief for sore throat and oral pain through local numbing and soothing agents.","indications":["Sore throat pain relief","Pharyngitis symptom management","Minor oral and throat irritation"],"catalyst":""},{"name":"Adalimumab - GP2017","genericName":"Adalimumab - GP2017","slug":"adalimumab-gp2017","phase":"phase_3","mechanism":"GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Adalimumab - US licensed Humira","genericName":"Adalimumab - US licensed Humira","slug":"adalimumab-us-licensed-humira","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Angal S, topical spray [Menthol]","genericName":"Angal S, topical spray [Menthol]","slug":"angal-s-topical-spray-menthol","phase":"phase_3","mechanism":"Menthol produces a cooling sensation by activating TRPM8 cold-sensitive receptors on nerve endings, providing topical analgesic and anti-inflammatory relief.","indications":["Topical relief of minor muscle and joint pain","Symptomatic relief of minor aches and pains associated with arthritis, backache, and sprains"],"catalyst":""},{"name":"Angal, lozenges [menthol],","genericName":"Angal, lozenges [menthol],","slug":"angal-lozenges-menthol","phase":"phase_3","mechanism":"Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough.","indications":["Sore throat pain and irritation","Cough suppression"],"catalyst":""},{"name":"Broncho-munal®","genericName":"Broncho-munal®","slug":"broncho-munal","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CIMERLI","genericName":"RANIBIZUMAB-EQRN","slug":"ranibizumab-eqrn","phase":"marketed","mechanism":"","indications":["Neovascular (Wet) Age-Related Macular Degeneration (AMD)","Macular Edema Following Retinal Vein Occlusion (RVO)","Diabetic Macular Edema (DME)","Diabetic Retinopathy (DR)","Myopic Choroidal Neovascularization (mCNV)"],"catalyst":""},{"name":"Canasa","genericName":"Canasa","slug":"canasa","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dopaminergic Agonists","genericName":"Dopaminergic Agonists","slug":"dopaminergic-agonists","phase":"marketed","mechanism":"Dopaminergic agonists activate dopamine receptors in the brain to increase dopamine signaling.","indications":["Parkinson's disease","Restless leg syndrome","Hyperprolactinemia"],"catalyst":""},{"name":"Duragesic","genericName":"Duragesic","slug":"duragesic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ENZEEVU","genericName":"AFLIBERCEPT-ABZV","slug":"aflibercept-abzv","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"EP2006","genericName":"EP2006","slug":"ep2006","phase":"phase_3","mechanism":"EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia in patients with chronic kidney disease","Chemotherapy-induced anemia in cancer patients"],"catalyst":""},{"name":"ERYPO®, Janssen-Cilag","genericName":"ERYPO®, Janssen-Cilag","slug":"erypo-janssen-cilag","phase":"phase_3","mechanism":"ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"GME751","genericName":"GME751","slug":"gme751","phase":"phase_3","mechanism":"GME751 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"GP2013","genericName":"GP2013","slug":"gp2013","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GP2013 - A Proposed biosimilar rituximab","genericName":"GP2013 - A Proposed biosimilar rituximab","slug":"gp2013-a-proposed-biosimilar-rituximab","phase":"phase_3","mechanism":"GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","indications":["Rheumatoid arthritis","Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia","Granulomatosis with polyangiitis","Microscopic polyangiitis"],"catalyst":""},{"name":"GP2015","genericName":"GP2015","slug":"gp2015","phase":"phase_3","mechanism":"GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells.","indications":["Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy"],"catalyst":""},{"name":"GP2015 Etanercept","genericName":"GP2015 Etanercept","slug":"gp2015-etanercept","phase":"phase_3","mechanism":"GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Plaque psoriasis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"GP2017 Adalimumab","genericName":"GP2017 Adalimumab","slug":"gp2017-adalimumab","phase":"phase_3","mechanism":"GP2017 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated disease activity.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Psoriasis","Ankylosing spondylitis"],"catalyst":""},{"name":"Generic tacrolimus","genericName":"Generic tacrolimus","slug":"generic-tacrolimus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucophage 1000 mg","genericName":"Glucophage 1000 mg","slug":"glucophage-1000-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HX575 epoetin alfa","genericName":"HX575 epoetin alfa","slug":"hx575-epoetin-alfa","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia","Anemia in patients with cancer"],"catalyst":""},{"name":"HX575 epoetin alfa (Sandoz)","genericName":"HX575 epoetin alfa (Sandoz)","slug":"hx575-epoetin-alfa-sandoz","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing major surgery"],"catalyst":""},{"name":"HX575 epoetin alfa Hexal AG","genericName":"HX575 epoetin alfa Hexal AG","slug":"hx575-epoetin-alfa-hexal-ag","phase":"phase_3","mechanism":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia","Anemia in patients with HIV infection"],"catalyst":""},{"name":"HX575 recombinant human erythropoietin alfa","genericName":"HX575 recombinant human erythropoietin alfa","slug":"hx575-recombinant-human-erythropoietin-alfa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HYRIMOZ","genericName":"ADALIMUMAB-ADAZ","slug":"adalimumab-adaz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Interleukin-3","genericName":"Interleukin-3","slug":"interleukin-3","phase":"marketed","mechanism":"Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages.","indications":["Bone marrow failure and aplastic anemia","Myelodysplastic syndromes","Chemotherapy-induced myelosuppression"],"catalyst":""},{"name":"JUBBONTI","genericName":"DENOSUMAB-BBDZ","slug":"denosumab-bbdz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Keytruda-EU","genericName":"Keytruda-EU","slug":"keytruda-eu","phase":"phase_3","mechanism":"Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"LA-EP2006","genericName":"LA-EP2006","slug":"la-ep2006","phase":"phase_3","mechanism":"LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor.","indications":["Anemia of chronic kidney disease","Chemotherapy-induced anemia"],"catalyst":""},{"name":"MabThera","genericName":"MabThera","slug":"mabthera","phase":"marketed","mechanism":"MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","indications":["Relapsed or refractory B-cell non-Hodgkin's lymphoma","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"Ocrevus-US","genericName":"Ocrevus-US","slug":"ocrevus-us","phase":"phase_3","mechanism":"Ocrevus-US is a monoclonal antibody that targets CD20 on B cells.","indications":["Relapsing multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Omnitrope","genericName":"Omnitrope","slug":"omnitrope","phase":"marketed","mechanism":"Growth hormone receptor","indications":["Growth retardation","Pituitary dwarfism","Prader-Willi syndrome","Severe growth hormone deficiency in adulthood","Turner syndrome"],"catalyst":""},{"name":"Originator rituximab - Rituxan ® or MabThera ®","genericName":"Originator rituximab - Rituxan ® or MabThera ®","slug":"originator-rituximab-rituxan-or-mabthera","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"TYRUKO","genericName":"NATALIZUMAB-SZTN","slug":"natalizumab-sztn","phase":"marketed","mechanism":"","indications":["Multiple Sclerosis","Crohn's Disease"],"catalyst":""},{"name":"US-licensed epoetin alfa","genericName":"US-licensed epoetin alfa","slug":"us-licensed-epoetin-alfa","phase":"phase_3","mechanism":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor.","indications":["Anemia associated with chronic kidney disease","Anemia associated with chemotherapy"],"catalyst":""},{"name":"ZIEXTENZO","genericName":"PEGFILGRASTIM-BMEZ","slug":"pegfilgrastim-bmez","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-01","type":"regulatory","headline":"Sandoz receives FDA approval for biosimilar rituximab","summary":"Sandoz announced that the US FDA has approved its biosimilar rituximab, a treatment for certain types of cancer.","drugName":"rituximab","sentiment":"positive"},{"date":"2022-08-01","type":"earnings","headline":"Sandoz reports strong Q2 2022 earnings","summary":"Sandoz reported strong earnings for the second quarter of 2022, driven by growth in its biosimilars business.","drugName":"","sentiment":"positive"},{"date":"2021-03-01","type":"deal","headline":"Sandoz partners with Biocon to develop biosimilars","summary":"Sandoz announced a partnership with Biocon to develop and commercialize biosimilars in several markets.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"European Stocks That May Be Trading Below Estimated Value In January 2026 - simplywall.st","headline":"European Stocks That May Be Trading Below Estimated Value In January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNXzR1ZGhodjVieGpwcXZoX2pyVFY0aWZkdXcyNFlmaTg5eEY4MzdqNy1BMG9KVnJUSEtGQ3NIRlByQnZBZ2V6WEJWaHJlX0Y3RExaWC1LNXVuUWFXMUFXZXZzRnk5ZjI3RXotcnJtbTcxbnF6cVNqQ1EtTHB3MWFqcXFZQzRFa0d5SGlQeA?oc=5","date":"2026-01-19","type":"pipeline","source":"Yahoo Finance","summary":"Are Investors Undervaluing Sandoz Group AG (VTX:SDZ) By 44%? - Yahoo Finance","headline":"Are Investors Undervaluing Sandoz Group AG (VTX:SDZ) By 44%?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-13","type":"pipeline","source":"simplywall.st","summary":"Sandoz Group AG's (VTX:SDZ) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced? - simplywall.st","headline":"Sandoz Group AG's (VTX:SDZ) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdW1oMkY1VnhMRWtZaVdqM1QtdmNmTnJFNGFrMGNwMktEdzdIMGg5d1pZN291MWxIak9SbU1yVlo5ZXRDenlBMmNqX0d6ckx5UGdNX3I2a3lQVF9JMDV5N0lXbG1BaWk5LVBqTHFSUHR1c3RSYmFqRE10dDZhd25WRWxja2xMOGJDVUpqbFNNSU9zeXdSbTZpV05TczJVdWxmZ3hLX3ZfSjdZaERWaGlGX3NsLTV4UDctY2dvSndtOE9HZl9zWUtLOW9jZGxoM1dy?oc=5","date":"2025-08-07","type":"patent","source":"Investing.com","summary":"Sandoz H1 2025 slides: Biosimilars drive growth as margins expand significantly - Investing.com","headline":"Sandoz H1 2025 slides: Biosimilars drive growth as margins expand significantly","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-15","type":"pipeline","source":"simplywall.st","summary":"Is Sandoz Group (VTX:SDZ) A Risky Investment? - simplywall.st","headline":"Is Sandoz Group (VTX:SDZ) A Risky Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9CTnduZGcxWmxwSk8yWXZwYmJEVjhaekNPZS1tTEhWcmxTV2FvN2l2d0pjejRaWC1RUERWdGU2SGZGck1XYlcwcDFkM0pUY2VxRG5OWjRueXlsUlBBM3VBV0pjaC14NVRDNzNlQmVIRQ?oc=5","date":"2025-02-06","type":"patent","source":"Morningstar","summary":"3 Generic Drug Stocks to Watch - Morningstar","headline":"3 Generic Drug Stocks to Watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5NOWZIUG0xRlVKSGVkazdKelRQQVpDTGxUc3ZXVHI5czY4Y0haZHBtU2VyZlo5UUhHdjdxazNWZVBWdnVJR1F6VFVvTnM4Wlk0cVJfYmM0dWpIdlZ3V3pBTGdpTQ?oc=5","date":"2024-03-21","type":"pipeline","source":"TradingView","summary":"SDZ Forecast — Price Target — Prediction for 2027 - TradingView","headline":"SDZ Forecast — Price Target — Prediction for 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPem1UdjhqaXhYMzZQNWRVYTlqcTdnaEN6QWlQRklSZkRLVTAwR2JzMUpKbXVTQWx1azlDb2JIZm5RYXdxWEJZLUlsWEtNNGc4U0ctUngzWWJPcjI3YzJZazBHNk5pSTVmdWRhd0NBbnFxeGJpWmJJSm12ckI4X2YwYmRrTm5seDJhWGg4Ui1nTE9ZaUdWeW1LUTZQRi1pN2szcEVWTjNRdFE3T0xQamxvdWhDTjhjM042U21DLURHSlNHZDd3WDZ5NGtxNE1SUUR5Y2xDSUk5YUdEVmFPRGxDTWdybGJWb1lBdllyZkVYNHJWX3FycWhHSm5qckVpLU5BSklHS0hMcjA?oc=5","date":"2023-11-27","type":"pipeline","source":"Newswire Canada","summary":"Sandoz Canada announces first ever list of Top 100 most important medicines, from a clinical standpoint, for Canadian patients - Newswire Canada","headline":"Sandoz Canada announces first ever list of Top 100 most important medicines, from a clinical standpoint, for Canadian pa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wWHo1R29Oa2VOS1IxWDZBOXJEaEplR25xbFN6WVhIa0JkSGtXTXZjQUQ3RmlJclhQMHdiZndPaTBmSlBuZVMzUFRiQ3JqVThTcXdJ?oc=5","date":"2023-10-20","type":"pipeline","source":"Yahoo Finance Australia","summary":"Sandoz Group AG (SDZNY) stock price, news, quote and history - Yahoo Finance Australia","headline":"Sandoz Group AG (SDZNY) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNZGQ2WnlIakIwa0dna2dmMUpwVkpVUmFsZkJqODh3YTM0SGJhbjZLQlFIZGVDVnVIUW5BUHgyQk4wd2c2SkVmbmoyQm9qN3VQSGNPeEs2QXNFSHJXdlJXNzlzdDV5ZEh0T1BuT0ZDc2pvblViMW9TVU1WRlNCaXRTMDlqbw?oc=5","date":"2023-10-07","type":"pipeline","source":"marketscreener.com","summary":"Sandoz Group AG: Shareholders Board Members Managers and Company Profile | CH1243598427 - marketscreener.com","headline":"Sandoz Group AG: Shareholders Board Members Managers and Company Profile | CH1243598427","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOZkFZZzZhMzJjbzhPdlJndGFaQWtfa19COUhpRXZkZkVfWWNwaGJ5QzJ4Mk9OdzMwQzdNa3VPVkp4QVRVbi1OREZEMjhYMWljN1lfQWNWcmQ3R0hYX3MzdVFmbnlaSmtSZUo3Q3hERGY4YWtDZWxHeU8wNWhlckZ6QzFncnlzZw?oc=5","date":"2023-10-06","type":"pipeline","source":"marketscreener.com","summary":"Sandoz Group AG: Target Price Consensus and Analysts Recommendations | SDZ | CH1243598427 - marketscreener.com","headline":"Sandoz Group AG: Target Price Consensus and Analysts Recommendations | SDZ | CH1243598427","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5pdlhocUI5NVFrMnVjNXlQR2lkbEFPc09ydnJib3pBendsclZlcmYzamc4WFJOeEhIWTFnQ0xuVEVFWHNMNmxjV05Pc3RENE83MlFIYnJPYw?oc=5","date":"2023-10-04","type":"pipeline","source":"TradingView","summary":"SDZ Stock Price and Chart — SIX:SDZ - TradingView","headline":"SDZ Stock Price and Chart — SIX:SDZ","sentiment":"neutral"}],"patents":[{"drugName":"Originator rituximab - Rituxan or MabThera","drugSlug":"rituximab","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Eylea EU","drugSlug":"aflibercept","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"EU","annualRevenue":1500000000}],"drugCount":44,"phaseCounts":{"phase_3":28,"marketed":14,"discontinued":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Mylan","Teva","Novartis"],"therapeuticFocus":["Oncology","Inflammatory conditions"],"financials":null,"yahoo":null}